Skip to content

Starling Oncology, Inc.

STLNW· NasdaqCore metricsCIK 1799191

Offices & clinics of doctors of medicine11 peers

Last sale
Aug 26, 2026
Market cap
—
no share count on file
Filings
552
$169.77M
Q3 2026+27.8% FY25 yoy
-$15.75M
Q3 2026N/M FY25 yoy
-$2.98M
Q3 2026N/M FY25 yoy
$16.66M
Q3 2026derivedN/M FY25 yoy
-$0.13
Q3 2026N/M FY25 yoy
$36.90M
Q3 2026−32.4% FY25 yoy

Price

$0.06556.67%$0.085past year
Aug 26, 2026 · IEX last sale
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$502.73MFY 2025
$502.73M0FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$502,729,000reported
FY 20242024-12-31$393,412,000reported
FY 20232023-12-31$324,239,000reported
FY 20222022-12-31$252,483,000reported
FY 20212021-12-31$203,003,000reported
FY 20202020-12-31$187,515,000reported

Capital returns

Dividends and buybacks · FY2021 to FY2024
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2024—$0.00$0.00—75.75M sh+1.9%—
FY2023—$1.02M$1.02M—74.31M sh−0.3%—
FY2022—$9.00M$9.00M—74.55M sh+1.8%—
FY2021—$0.00$0.00—73.25M sh+218.5%—

Segments

Revenue by Segments, FY2020 to FY2025FY2020Patient services · FY2020 · $116.82MClinical trials & other · FY2020 · $6.81MDispensary · FY2020 · $63.89MFY2021Patient services · FY2021 · $124.07MClinical trials & other · FY2021 · $6.38MDispensary · FY2021 · $72.55MFY2022Patient services · FY2022 · $166.79MClinical trials & other · FY2022 · $6.36MDispensary · FY2022 · $79.34MFY2023Patient services · FY2023 · $213.50MClinical trials & other · FY2023 · $6.90MDispensary · FY2023 · $103.84MFY2024Specialty pharmacy · FY2024 · $179.92MPatient services · FY2024 · $204.88MClinical trials & other · FY2024 · $8.61MDispensary · FY2024 · $179.92MFY2025Specialty pharmacy · FY2025 · $269.18MPatient services · FY2025 · $228.99MClinical trials & other · FY2025 · $4.56M
LineFY2025ShareChange
Specialty pharmacy$269.18M54%+49.6%
Patient services$228.99M46%+11.8%
Clinical trials & other$4.56M0.9%−47.0%
Dispensary———
Total$502.73M

From the 10-K filed Mar 12, 2026STLNW

Offices & clinics of doctors of medicine

Starling Oncology, Inc. is the 3rd largest of the 12 covered companies the SEC files under this code, by revenue. SIC 8011

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR